Alpelisib hydrochloride is a potent and selective inhibitor of PI3Kα with an IC50 of 0.005 μM, 1.2 μM, 0.29 μM, 0.25 μM for p110α, p110β, p110δ, p110γ, respectively. It exhibits good efficacy in inhibiting the growth of PI3Ka driven tumors and can be used in cancer research.

Alpelisib hydrochloride is a potent and selective inhibitor of PI3Kα with an IC50 of 0.005 μM, 1.2 μM, 0.29 μM, 0.25 μM for p110α, p110β, p110δ, p110γ, respectively. It exhibits good efficacy in inhibiting the growth of PI3Ka driven tumors and can be used in cancer research.

ABBV-969 Payload is an agent-linker conjugate with a potent inhibitor of topoisomerase I and a linker designed for use in the antibody-drug conjugate (ADC) ABBV-969. It can be used in non-small cell lung cancer research.

Alpelisib hydrochloride is a potent and selective inhibitor of PI3Kα with an IC50 of 0.005 μM, 1.2 μM, 0.29 μM, 0.25 μM for p110α, p110β, p110δ, p110γ, respectively. It exhibits good efficacy in inhibiting the growth of PI3Ka driven tumors and can be used in cancer research.

YJ9069 is a potent, selective and orally bioavailable PROTAC degrader of CDK12/CDK13. It inhibits proliferation in prostate cancer cells by inducing gene-length-dependent transcriptional elongation defects, leading to DNA damage, cell-cycle arrest, and significant tumor growth suppression in vivo.

YJ9069 is a potent, selective and orally bioavailable PROTAC degrader of CDK12/CDK13. It inhibits proliferation in prostate cancer cells by inducing gene-length-dependent transcriptional elongation defects, leading to DNA damage, cell-cycle arrest, and significant tumor growth suppression in vivo.

ATC-324 is a potent AUTOphagy-TArgeting Chimera (AUTOTAC) degrader of androgen receptor (AR) with a DC50 of 2.05 µM. It induces autophagy–lysosomal degradation of AR, reduces nuclear AR and AR-V7 activity, and causes cytotoxicity in AR-positive prostate cancer cells, making it useful for prostate cancer research.

MCT-IN-1 (compound 2) is a potent and selective inhibitor of monocarboxylate transporter (MCT), with the IC50 of 9 nM and 14 nM for MCT1 and MCT4, respectively. It can be used in research as a potential target for overcoming multidrug resistance (MDR) in cancer.

YX968 is a potent, rapid, and selective PROTAC dual degrader of HDAC3/8 with DC50 values of 1.7 nM and 6.1 nM, respectively. It promotes apoptosis and kills cancer cells with a high potency in vitro and can be used in cancer research.

Amezalpat is a first-in-class, oral, competitive antagonist of peroxisome proliferator-activated receptor α (PPARα), with IC50 of 0.04 µM. It inhibits fatty acid oxidation (FAO), disrupting cancer cell metabolism and restoring immune responses, and shows antitumor activity in research on advanced solid tumors.